NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Zoetis Inc. ZTS
15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY12 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$9.5B
▲ 2.3% vs FY2024
Dividend streak
12 yrs
Raised every year since 2014
EPS · FY25
—
Dividend / sh · FY25
$2.03
Payout · FY25
—
ROE · FY25
66.0%
Net margin · FY25
28.2%
Dividend coverage
3.0×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 9.5B
Revenue, FY2025 · full 15-year series below
Revenue
Net income
28 cents of every revenue dollar became profit this year.
Per share
—
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 3.0 times — the rest stayed in the company.
Profitability
66.0%
Return on equity, FY2025
ROE
Operating margin35.5%
Net margin28.2%
Return on assets18.0%
Each USD of equity produced 66 cents of profit this year.
Returned to shareholders
USD 3.2B
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 3.2B
Share of profit120.7%
Consecutive raises12 years
USD 3.2B in buybacks — 121% of the year's profit, so the payout drew on cash built up earlier.
Growth
+7.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.4%
+7.2%
+7.1%
Net income
+8.1%
+10.3%
+22.9%
EPS, diluted
+10.3%
+12.0%
+24.4%
Dividend / share
+14.6%
+19.0%
+19.4%
Returned to shareholders
+26.9%
+75.6%
+32.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years−10.6%
Change, 10 years−14.6%
The share count shrank 11% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 15.5B
total assets, end of FY2025
Total assetsUSD 15.5B
EquityUSD 3.3B
CashUSD 2.3B
Gross debtUSD 9.0B
Net debtUSD 6.7B
Current ratio3.03×
Net debt stands at 202% of equity.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
9.5
9.3
8.5
8.1
7.8
6.7
6.3
5.8
5.3
4.9
4.8
4.8
4.6
4.3
4.2
Operating income $B
3.4
3.1
2.9
2.7
2.5
2.0
1.8
1.7
1.5
1.2
0.5
0.8
0.7
0.7
0.4
EBITDA $B
3.8
3.6
3.4
3.1
2.9
2.4
2.2
2.0
1.8
1.5
0.7
1.0
0.9
0.9
0.6
Income tax $B
0.7
0.6
0.6
0.5
0.5
0.4
0.3
0.3
0.7
0.4
0.2
0.2
0.2
0.3
0.1
Net income $B
2.7
2.5
2.3
2.1
2.0
1.6
1.5
1.4
0.9
0.8
0.3
0.6
0.5
0.4
0.2
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
2.03
1.80
1.56
1.35
1.07
0.85
0.69
0.54
0.44
0.39
0.34
0.30
0.27
0.00
0.00
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
66.0
50.9
49.9
47.3
49.0
50.6
61.3
72.2
53.1
64.3
28.5
51.8
20.3
10.8
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed